Latest in Biogen’s
Sort by
4 items
-
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing ...Business - MarketWatch - November 14 -
Biogen’s stock hit by soft sales of Alzheimer’s treatment
“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company’s CEO said.Business - MarketWatch - October 30 -
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.Business - CNBC - October 30